期刊文献+
共找到517篇文章
< 1 2 26 >
每页显示 20 50 100
Exploring the impact of hepatitis B immunoglobulin and antiviral interventions to reduce vertical transmission of hepatitis B virus
1
作者 Dhita Prabasari Wibowo Agustiningsih Agustiningsih +2 位作者 Sri Jayanti Caecilia H C Sukowati Korri Elvanita ElKhobar 《World Journal of Experimental Medicine》 2024年第4期6-22,共17页
Hepatitis B virus(HBV)infection is a major public health burden.In HBV endemic regions,high prevalence is also correlated with the infections acquired in infancy through perinatal transmission or early childhood expos... Hepatitis B virus(HBV)infection is a major public health burden.In HBV endemic regions,high prevalence is also correlated with the infections acquired in infancy through perinatal transmission or early childhood exposure to HBV,the socalled mother-to-child transmission(MTCT).Children who are infected with HBV at a young age are at higher risk of developing chronic HBV infection than those infected as adults,which may lead to worse clinical outcome.To reduce the incidence of HBV MTCT,several interventions for the infants or the mothers,or both,are already carried out.This review explores the newest information and approaches available in literature regarding HBV MTCT prevalence and its challenges,especially in high HBV endemic countries.This covers HBV screening in pregnant women,prenatal intervention,infant immunoprophylaxis,and postvaccination serological testing for children. 展开更多
关键词 hepatitis b virus hepatitis b immunoglobulin Mother-to-child transmission Vertical transmission Antiviral prophylaxis
下载PDF
Impact of hepatitis B immunoglobulin mode of administration on treatment experiences of patients after liver transplantation: Results from an online survey
2
作者 Giorgia Rizza Kyriaki Glynou Masha Eletskaya 《World Journal of Transplantation》 2024年第3期144-155,共12页
BACKGROUND Hepatitis B immunoglobulin(HBIG)in combination with a potent nucleos(t)ide analog is considered the standard of care for prophylaxis against hepatitis B virus(HBV)reinfection after liver transplantation for... BACKGROUND Hepatitis B immunoglobulin(HBIG)in combination with a potent nucleos(t)ide analog is considered the standard of care for prophylaxis against hepatitis B virus(HBV)reinfection after liver transplantation for HBV-associated disease.AIM To evaluate patients’satisfaction,preferences,and requirements for subcutaneous(SC),intramuscular(IM),and intravenous(IV)HBIG treatments.METHODS A self-completion,cross-sectional,online,22-question survey was conducted to examine perceptions and satisfaction with current HBIG treatment in adults receiving HBIG treatment following liver transplantation for HBV-associated disease in France,Italy,and Turkey.Hypothetical HBIG products with different administration modes were evaluated using target product profile assessment and a conjoint(trade-off)exercise.RESULTS Ninety patients were enrolled;32%,17%,and 51%were SC,IM,and IV HBIG users,respectively.Mean duration of treatment was 36.2 months.SC HBIG had the least negative impact on emotional well-being and social life and was perceived as the most convenient,easiest to administer,least painful,and had the highest self-rating of treatment compliance.More IM HBIG users than SC or IV HBIG users reported that administration frequency was excessive(67%,28%,and 28%,respectively).In the target product profile assessment,76%of patients were likely to use hypothetical SC HBIG.In the conjoint exercise,administration route,frequency,and duration were key drivers of treatment preferences.CONCLUSION Ease,frequency,duration,and side effects of HBIG treatment administration were key drivers of treatment preferences,and SC HBIG appeared advantageous over IM and IV HBIG for administration ease,convenience,and pain.A hypothetical SC HBIG product elicited a favorable response.Patient demographics,personal preferences,and satisfaction with HBIG treatment modalities may influence long-term treatment compliance. 展开更多
关键词 hepatitis b immunoglobulin Liver transplantation SUbCUTANEOUS INTRAMUSCULAR INTRAVENOUS Patient satisfaction
下载PDF
肝移植术后乙肝主动免疫重建受者停用HBIG和(或)核苷(酸)类似物的长期安全性和有效性 被引量:1
3
作者 武凤 段斌炜 +3 位作者 欧阳雅博 张静 曹宇 栗光明 《器官移植》 CAS CSCD 北大核心 2024年第3期435-442,共8页
目的探讨乙型病毒性肝炎(乙肝)相关疾病肝移植受者接种乙肝疫苗成功后长期停用乙型肝炎免疫球蛋白(HBIG)和(或)核苷(酸)类似物(NAs)预防乙型肝炎病毒(HBV)再感染的安全性及有效性。方法回顾性分析76例接种乙肝疫苗后成功重建乙肝主动免... 目的探讨乙型病毒性肝炎(乙肝)相关疾病肝移植受者接种乙肝疫苗成功后长期停用乙型肝炎免疫球蛋白(HBIG)和(或)核苷(酸)类似物(NAs)预防乙型肝炎病毒(HBV)再感染的安全性及有效性。方法回顾性分析76例接种乙肝疫苗后成功重建乙肝主动免疫的肝移植受者的基本资料,分析疫苗接种及应答情况、应答者停用HBIG和(或)NAs的随访结果、停用HBIG和(或)NAs后HBV再感染情况。结果肝移植术后至开始接种乙肝疫苗的时间间隔为26(20,40)个月。接种疫苗至应答时间为15(8,27)个月。初始76例受者全部停用HBIG,36例受者停用HBIG和NAs。随访期间,76例停用HBIG受者中12例恢复使用HBIG,36例停用HBIG和NAs者中16例恢复使用NAs。HBIG和NAs停用时间分别为135(98,150)个月与133(34,149)个月。16例应答者未接种过加强针,36例应答者定期接种加强针,第1次接种加强针的时间距离停用HBIG的间隔时间为44(11,87)个月,未接种加强针和接种加强针的应答者一般资料比较差异均无统计学意义(均为P>0.05)。截至随访日,9例受者失访,5例HBV再感染,3例受者死亡,1例受者移植物丢失并进行二次肝移植。5例HBV再感染受者中4例发生病毒变异。再感染者与未感染者是否停用过NAs、移植前乙型肝炎e抗原(HBeAg)是否为阳性差异有统计学意义(均为P<0.05)。结论乙肝相关疾病肝移植术后乙肝主动免疫重建成功的受者长期停用HBIG是可行和安全的,但能否同时停用NAs还需要进一步研究。 展开更多
关键词 肝移植 乙型肝炎免疫球蛋白 核苷(酸)类似物 主动免疫 免疫重建 疫苗接种 乙型肝炎病毒 再感染
下载PDF
Immunoprophylaxis failure and vaccine response in infants born to mothers with chronic hepatitis B infection in Djibouti
4
作者 Sahal Darar Dirir Ambroise D Ahouidi +6 位作者 Aboubacry Drame Warsama Osman Abdi Guelleh Youssouf Kayad Mohamed Houmed Aboubakar Makhtar Camara Coumba Toure Kane Halimatou Diop Ndiaye 《World Journal of Hepatology》 2024年第7期1039-1050,共12页
BACKGROUND In endemic areas,vertical transmission of hepatitis B virus(HBV)remains a major source of the global reservoir of infected people.Eliminating mother-to-child transmission(MTCT)of HBV is at the heart of Worl... BACKGROUND In endemic areas,vertical transmission of hepatitis B virus(HBV)remains a major source of the global reservoir of infected people.Eliminating mother-to-child transmission(MTCT)of HBV is at the heart of World Health Organization’s goal of reducing the incidence of HBV in children to less than 0.1%by 2030.Universal screening for hepatitis B during pregnancy and neonatal vaccination are the main preventive measures.AIM To evaluate the efficacy of HBV vaccination combined with one dose of immunoglobulin in children born to hepatitis B surface antigen(HBsAg)-positive mothers in Djibouti city.METHODS We conducted a study in a prospective cohort of HBsAg-positive pregnant women and their infants.The study ran from January 2021 to May 2022,and infants were followed up to 7 mo of age.HBV serological markers and viral load in pregnant women were measured using aVidas microparticle enzyme-linked immunosorbent assay(Biomérieux,Paris,France)and the automated Amplix platform(Biosynex,Strasbourg,France).All infants received hepatitis B immunoglobulin and were vaccinated against HBV at birth.These infants were closely monitored to assess their seroprotective response and for failure of immunoprophylaxis.Simple logistic regression was also used to identify risk factors associated with immunoprophylaxis failure and poor vaccine response.All statistical analyses were performed with version 4.0.1 of the R software.RESULTS Of the 50 pregnant women recruited,the median age was 31 years,ranging from 18 years to 41 years.The MTCT rate in this cohort was 4%(2/50)in HBsAg-positive women and 67%(2/3)in hepatitis B e antigen-positive women with a viral load>200000 IU/mL.Of the 48 infants who did not fail immunoprophylaxis,8(16%)became poor responders(anti-HB<100 mIU/mL)after HBV vaccination and hepatitis B immunoglobulin,while 40(84%)infants achieved a good level of seroprotection(anti-HB>100 mIU/mL).Factors associated with this failure of immunoprophylaxis were maternal HBV DNA levels(>200000 IU/mL)and hepatitis B e antigen-positive status(odds ratio=158,95%confidence interval:5.05-4958,P<0.01).Birth weight<2500 g was associated with a poor immune response to vaccination(odds ratio=34,95%confidence interval:3.01-383.86,P<0.01).CONCLUSION Despite a failure rate of immunoprophylaxis higher than the World Health Organization target,this study showed that the combination of immunoglobulin and HBV vaccine was effective in preventing MTCT of HBV.Therefore,further studies are needed to better understand the challenges associated with immunoprophylaxis failure in infants in Djibouti city. 展开更多
关键词 hepatitis b surface antigen INFANTS hepatitis b immunoglobulin hepatitis vaccine DJIbOUTI
下载PDF
Demyelinating neuropathy in patients with hepatitis B virus: A case report
5
作者 Xiao-Xiao Yan Jin Huang Jing Lin 《World Journal of Clinical Cases》 SCIE 2024年第10期1766-1771,共6页
BACKGROUND Hepatitis B rarely leads to demyelinating neuropathy,despite peripheral neuropathy being the first symptom of hepatitis B infection.CASE SUMMARY A 64-year-old man presented with sensorimotor symptoms in mul... BACKGROUND Hepatitis B rarely leads to demyelinating neuropathy,despite peripheral neuropathy being the first symptom of hepatitis B infection.CASE SUMMARY A 64-year-old man presented with sensorimotor symptoms in multiple peripheral nerves.Serological testing showed that these symptoms were due to hepatitis B.After undergoing treatment involving intravenous immunoglobulin and an antiviral agent,there was a notable improvement in his symptoms.CONCLUSION Although hepatitis B virus(HBV)infection is known to affect hepatocytes,it is crucial to recognize the range of additional manifestations linked to this infection.The connection between long-term HBV infection and demyelinating neuropathy has seldom been documented;hence,prompt diagnostic and treatment are essential.The patient's positive reaction to immunoglobulin seems to be associated with production of the antigen-antibody immune complex. 展开更多
关键词 hepatitis b virus infection Extrahepatic manifestations Demyelinating neuropathy Intravenous immunoglobulin Electroneuromyography Case report
下载PDF
LAM联合HBIG在HBV母婴传播中的阻断效果及安全性 被引量:1
6
作者 李玲玲 毛玉萍 周莹 《中外医学研究》 2023年第4期43-48,共6页
目的:研究拉米夫定(Lamivudine,LAM)联合乙型肝炎免疫球蛋白(hepatitis B immunoglobulin,HBIG)对乙型肝炎病毒(hepatitis B virus,HBV)母婴传播的阻断效果及安全性。方法:回顾性选取2017年12月—2019年12月麻城市人民医院105例HBV感染... 目的:研究拉米夫定(Lamivudine,LAM)联合乙型肝炎免疫球蛋白(hepatitis B immunoglobulin,HBIG)对乙型肝炎病毒(hepatitis B virus,HBV)母婴传播的阻断效果及安全性。方法:回顾性选取2017年12月—2019年12月麻城市人民医院105例HBV感染孕妇为样本。根据治疗方案不同将其分为联合组(n=74)和LAM组(n=31)。LAM组接受LAM治疗,联合组接受LAM联合HBIG治疗。比较两组治疗前及临产前HBV标志物(HBVM)水平、HBV-DNA载量、肝功能指标,新生儿健康情况,新生儿HBV感染情况。分析药物安全性。结果:临产前,两组HBcAb、HBeAg及HBV-DNA水平均明显降低(P<0.05),且联合组HBeAg和HBV-DNA水平均低于LAM组(P<0.05)。临产前,两组谷丙转氨酶(ALT)、谷草转氨酶(AST)及总胆红素(TBIL)水平均明显升高(P<0.05),两组ALT、AST及TBIL水平比较差异均无统计学意义(P>0.05)。两组新生儿体重、10 min Apgar评分及新生儿肺炎、窒息和畸形发生率比较差异均无统计学意义(P>0.05)。接种疫苗前,联合组新生儿HBsAg阳性率低于LAM组(P<0.05),接种疫苗后1个月,两组HBsAg阳性率均明显降低,两组HBs Ag和抗-HBs阳性率比较差异均无统计学意义(P>0.05)。治疗期间,联合组孕妇发生一过性ALT水平轻度升高1例(1.89%),新生儿黄疸1例(1.89%),肌酸激酶升高2例(3.77%);LAM组孕妇未见明显异常,新生儿发生高胆红素血症1例(1.89%),均未予特殊处理,观察1周后自行恢复正常。结论:LAM联合HBIG阻断HBV母婴垂直传播可有效降低孕妇血液中病毒滴度和复制水平,降低新生儿宫内感染风险。 展开更多
关键词 乙肝病毒 母婴传播 宫内感染 阻断 拉米夫定 乙肝肝炎免疫球蛋白
下载PDF
A randomized controlled clinical trial: Interruption of intrauterine transmission of hepatitis B virus infection with HBIG 被引量:26
7
作者 Qin XH Lin Xi-ao +2 位作者 Xiao-Bo Lu Yue-Xin Zhang Xia Cai 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第21期3434-3437,共4页
AIM: To evaluate the efficacy of interruption of intrauterine infection of HBV with HBIG in pregnant women with positive HBeAg and HBsAg.METHODS: A prospective randomized controlled trial was adopted. Sixty cases wi... AIM: To evaluate the efficacy of interruption of intrauterine infection of HBV with HBIG in pregnant women with positive HBeAg and HBsAg.METHODS: A prospective randomized controlled trial was adopted. Sixty cases with positive HBeAg and HBsAg were coincident with the criteria of inclusion, and 8 cases were excluded. Fifty-two cases were analyzed (28 cases in trial group and 24 in control group). All cases in trial group received 200 IU HBIG intravenously every 4 wk for 3 times from the 28^th wk. The cases of control group received placebo in the same way. All pregnant women were detected for HBeAg and HBV-DNA at the beginning of the trial and end of the trial (delivery). The cord blood of all newborns were collected for detecting HBeAg and HBV-DNA simultaneously.RESULTS: For investigation of HBeAg of newborns in trial group, 6 of 28 cases of newborns had positive HBeAg, the HBeAg positive rate being 21.4%, the total rate of 95% CI being 8%-41%. In control group, 19 of 24 cases of newborns had positive HBeAg, HBeAg positive rate was 79.2%, the rate of 95%CI being 5%-93%. By statistical analysis, 2= 17.26, P 〈 0.01, RR = 0.27, 95% CI (6.3 × 10^-6, 8.6 × 10^-5). For investigation of HBV-DNA of newborns in trial group, 7 of 28 cases of newborns had positive HBV-DNA, HBV-DNA positive rate being 25%, the total rate of 95% CI being 11%-45%. In control group, 20 of 24 cases of newborns had positive HBV-DNA, HBV-DNA positive rate was 83.3%, the total rate of 95% CI being 63%-95%. By statistical analysis, X^2 = 17.62, P 〈 0.01, RR = 0.30, 95% CI (1.5 × 10^-5, 1.7× 10^-4). The results indicated that there was significant difference in HBeAg positive rate and HBV-DNA positive rate of newborns between the two groups. In trial group, 7 of 28 newborns had HBV-DNA positive, but the HBV-DNA load of newborns was lower than that of their mothers. In control group, 20 of 24 newborns still had HBV-DNA positive, and the HBV-DNA load of newborns was close to those of their mothers. Statistical analysis indicated that there was no significant difference in HBV- DNA load between postnatal women without HBIG intervention and their filial generations (T = 81.5, P 〉 0.1). CONCLUSION: It is effective and safe to prevent intrauterine infection of HBV with HBIG from the 28^th wk in pregnant women with positive HBeAg and HBsAg. In clinical application, those pregnant women with negative HBeAg and positive HBV-DNA also need to be interrupted by HBIG. 展开更多
关键词 INTERRUPTION INTRAUTERINE TRANSMISSION hepatitis b virus hbig
下载PDF
Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon 被引量:2
8
作者 Nada M Melhem Rami A Mahfouz +5 位作者 Khalil Kreidieh Rabab Abdul-Khalik Rolla El-Khatib Reem Talhouk Umayya Musharrafieh Ghassan Hamadeh 《World Journal of Hepatology》 CAS 2016年第29期1212-1221,共10页
AIMTo explore the role of killer immunoglobulin receptor (KIR) genes in responsiveness or non-responsiveness to vaccination against hepatitis B virus. METHODSWe recruited 101 voluntary participants between March 2010 ... AIMTo explore the role of killer immunoglobulin receptor (KIR) genes in responsiveness or non-responsiveness to vaccination against hepatitis B virus. METHODSWe recruited 101 voluntary participants between March 2010 and December 2011. Sera samples from vaccinated and non-vaccinated participants were tested for the presence of anti-HBs antibodies as a measure of protection against hepatitis B, hepatitis B surface antigen and hepatitis B core antibody as indicators of infection by enzyme-linked immunosorbent assay. KIR gene frequencies were determined by polymerase chain reaction. RESULTSSera samples from 99 participants were tested for the levels of anti-HBs as an indicator of protection (&ge; 10 mIU/mL) following vaccination as defined by the World Health Organization international reference standard. Among the vaccinated participants, 47% (35/74) had anti-HBs titers above 100 mIU/mL, 22% (16/74) had anti-HBs ranging between 10-100 mIU/mL, and 20% (15/74) had values of less than 10 mIU/mL. We report the lack of significant association between the number of vaccine dosages and the titer of antibodies among our vaccinated participants. The inhibitory KIR2DL1, KIR2DL4, KIR3DL1, KIR3DL2, and KIR3DL were detected in more than 95%, whereas KIR2DL2, KIR2DL3, KIR2DL5 (KR2DL5A and KIR2DL5B) were expressed in 56%, 84% and 42% (25% and 29%) of participants, respectively. The observed frequency of the activating KIR genes ranged between 35% and 55% except for KIR2DS4, detected in 95% of the study participants (40.6% 2DS4*001/002; 82.2% 2DS4*003/007). KIR2DP1 pseudogene was detected in 99% of our participants, whereas KIR3DP*001/02/04 and KIR3DP1*003 had frequencies of 17% and 100%, respectively. No association between the frequency of KIR genes and anti-HBs antibodies was detected. When we compared the frequency of KIR genes between vaccinated individuals with protective antibodies titers and those who lost their protective antibody levels, we did not detect a significant difference. KIR2DL5B was significantly different among different groups of vaccinated participants (group I > 100 mIU/mL, group II 10-100 mIU/mL, group III CONCLUSIONTo our knowledge, this is the first study screening for the possible role of KIR genes among individuals vaccinated against hepatitis B virus (HBV). Our results can be used to design larger studies to better understand the role of KIR genes in protection against or susceptibility to HBV post vaccination. 展开更多
关键词 hepatitis b virus Killer immunoglobulin receptors hepatitis b vaccine Lebanon Natural killer cells
下载PDF
替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析 被引量:6
9
作者 陈嵘 黄美玲 +4 位作者 凌雪梅 林小红 曾俊 黎云 夏建红 《实用肝脏病杂志》 CAS 2019年第5期752-753,共2页
目的探讨应用替比夫定联合乙型肝炎高效价免疫球蛋白(HBIG)和乙肝疫苗阻断乙型肝炎病毒(HBV)母婴传播的临床效果。方法在HBV感染孕妇197例中,92例在孕7月时开始口服替比夫定至分娩后3个月,两组新生儿均接受标准HBIG和乙肝疫苗接种。随... 目的探讨应用替比夫定联合乙型肝炎高效价免疫球蛋白(HBIG)和乙肝疫苗阻断乙型肝炎病毒(HBV)母婴传播的临床效果。方法在HBV感染孕妇197例中,92例在孕7月时开始口服替比夫定至分娩后3个月,两组新生儿均接受标准HBIG和乙肝疫苗接种。随访12个月。结果研究组孕妇分娩时血清HBV DNA水平显著低于对照组(P<0.05);研究组新生儿出生24 h和出生1个月宫内感染率均为6.7%,显著低于对照组(分别为19.6%和22.8%,P<0.05);研究组新生儿出生12个月后HBsAg阳性率和HBV DNA阳性率分别为5.7%和0.9%,显著低于对照组(分别为19.6%和9.8%,P<0.05),血清抗-HBs阳性率为94.3%,显著高于对照组的84.8%(P<0.05)。结论应用替比夫定联合HBIG和乙肝疫苗能够有效抑制孕妇HBV DNA复制,降低新生儿宫内感染率,提高抗-HBs阳性率,对新生儿有良好的保护效果。 展开更多
关键词 乙型肝炎 替比夫定 乙型肝炎高价免疫球蛋白 乙肝疫苗 母婴传播 孕妇
下载PDF
HBIG阻断乙型肝炎病毒母婴传播 被引量:7
10
作者 崔恒春 闫永平 +4 位作者 邵中军 徐德忠 门可 徐剑秋 李军 《第四军医大学学报》 北大核心 2006年第11期1027-1030,共4页
目的:评价HBsAg阳性母亲孕晚期肌注HBIG(乙肝免疫球蛋白)及婴儿出生后HBIG联合乙肝疫苗对HBV母婴传播及慢性化阻断的效果.方法:历史对照组只对婴儿进行乙肝疫苗的全程免疫;HBIG组母亲孕晚期3mo每月肌注200u的HBIG;婴儿出生时、半月龄时... 目的:评价HBsAg阳性母亲孕晚期肌注HBIG(乙肝免疫球蛋白)及婴儿出生后HBIG联合乙肝疫苗对HBV母婴传播及慢性化阻断的效果.方法:历史对照组只对婴儿进行乙肝疫苗的全程免疫;HBIG组母亲孕晚期3mo每月肌注200u的HBIG;婴儿出生时、半月龄时分别肌注200u的HBIG,并常规接种乙肝疫苗.随访两组婴儿HBsAg变化情况,采用历史对照临床试验评价母亲及新生儿注射HBIG对HBV母婴传播及慢性化的阻断效果.结果:历史对照组HBV宫内感染率5.34%,随访时婴儿HBsAg转阳率5.15%,HBV感染慢性化率87.5%;HBIG组分别为5.26%,0,18.18%.经统计学检验,两组HBV宫内感染率无显著差异(P=1.000),但婴儿HBsAg转阳率及HBV感染慢性化率具有显著差异(P分别为0.019,0.001).结论:母亲孕晚期注射HBIG对阻断HBV宫内传播效果不明显;母亲及新生儿注射HBIG可显著提高乙肝疫苗对婴儿出生后HBsAg阳转及HBV感染慢性化的阻断效果. 展开更多
关键词 乙型肝炎病毒 垂直传播 免疫球蛋白类
下载PDF
单用拉米夫定及其与HBIG联用预防肝移植术后HBV复发效果比较的meta分析 被引量:2
11
作者 旷翠萍 栾荣生 +3 位作者 魏宪义 严律南 贾继东 李佳圆 《现代预防医学》 CAS 北大核心 2008年第1期19-21,共3页
[目的]综合评估比较单用拉米夫定、乙肝免疫球蛋白(HBIG)和拉米夫定联用这两种预防乙肝相关性肝病肝移植术后HBV复发方案的效果。[方法]采用meta分析方法,对检索并入选的5篇国内外比较单用拉米夫定、HBIG和拉米夫定联用这两种预防方案... [目的]综合评估比较单用拉米夫定、乙肝免疫球蛋白(HBIG)和拉米夫定联用这两种预防乙肝相关性肝病肝移植术后HBV复发方案的效果。[方法]采用meta分析方法,对检索并入选的5篇国内外比较单用拉米夫定、HBIG和拉米夫定联用这两种预防方案的临床对照试验进行综合定量分析。[结果]单用拉米夫定与HBIG和拉米夫定联用比较,病人肝移植术后1年复发率、2年复发率和乙肝病毒YMDD变异发生率均较高,合计OR值(95%CI)分别为4.91(1.8~13.30)、4.93(2.72~8.94)、3.79(1.81~7.90)。[结论]预防乙肝相关性肝移植术后乙肝复发,HBIG与拉米夫定联用方案比单用拉米夫定方案效果好。 展开更多
关键词 乙肝免疫球蛋白 拉米夫定 乙肝病毒 肝移植 复发 YMDD变异 META分析
下载PDF
HBIG-PBCA-NP对QSG、HepG及PBMC细胞增长率及毒性的影响 被引量:1
12
作者 彭忠田 谭德明 +2 位作者 黄顺玲 朱平安 刘菲 《山东医药》 CAS 北大核心 2010年第11期25-27,共3页
目的研究乙型肝炎免疫球蛋白(HBIG)聚氰基丙烯酸正丁酯纳米粒(HBIG—PBCA—NP)、PBCA—NP的体外应用安全性。方法用乳化聚合法分别制备HBIG-PBCA-NP、PBCA-NP;采用MTT比色法研究不同浓度的HBIG-PBCA-NP、PBCA—NP对外周血单核细胞... 目的研究乙型肝炎免疫球蛋白(HBIG)聚氰基丙烯酸正丁酯纳米粒(HBIG—PBCA—NP)、PBCA—NP的体外应用安全性。方法用乳化聚合法分别制备HBIG-PBCA-NP、PBCA-NP;采用MTT比色法研究不同浓度的HBIG-PBCA-NP、PBCA—NP对外周血单核细胞(PBMC)、QSG7701细胞及HepG2.2.15细胞生长抑制作用的影响;用自动生化仪测定乳酸脱氢酶(LDH)、丙氨酸转氨酶(ALT)活性。结果按相对生长率(RGR%),HBIG—PBCA—NP、PBCA—NP对PBMC、QSG7701细胞及HepG2.2.15细胞的毒性分级分别为0—1级,LDH与ALT释放值与HBIG、空白对照相比,差异无显著性(P〉0.01)。结论PBCA—NP属无毒级载体,HBIG—PBCA—NP具有良好的细胞生物安全性。 展开更多
关键词 乙型肝炎免疫球蛋白 乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒 MTT比色法 外周血单个核细胞 QSG7701细胞 HEPG2.2.15细胞
下载PDF
产前注射HBIG及新生儿HBIG联合乙肝疫苗预防乙肝病毒母婴传播 被引量:3
13
作者 郑九生 张红玲 +5 位作者 夏丽琴 雷钧 王晨 王佳春 黄慧英 甘雪华 《实用临床医学(江西)》 CAS 2006年第6期21-23,共3页
目的:探讨乙肝表面抗原(HBsAg)阳性母亲产前用乙肝免疫球蛋白(HBIG)及婴儿HBIG联合乙肝疫苗阻断母婴传播的效果。方法:2004年1月至2006年4月在江西省妇幼保健院产前检查、住院分娩的HBsAg阳性孕妇366例,研究组186例(HBsAg及HBeAg双阳性6... 目的:探讨乙肝表面抗原(HBsAg)阳性母亲产前用乙肝免疫球蛋白(HBIG)及婴儿HBIG联合乙肝疫苗阻断母婴传播的效果。方法:2004年1月至2006年4月在江西省妇幼保健院产前检查、住院分娩的HBsAg阳性孕妇366例,研究组186例(HBsAg及HBeAg双阳性66例),对照组180例(HBsAg及HBeAg双阳性60例)。研究组于28、32、36周肌肉注射HBIG200 IU,共3次,对照组不用药。所有新生儿出生时采静脉血1 mL,出生后24 h内注射HBIG200 IU,按0,1,6个月龄接种乙肝疫苗,5μg/次,随访至1岁时采婴儿静脉血1 mL,采用酶联免疫法检测新生儿出生时和1岁时静脉血清HBsAg、HBsAb、HBeAg、HBeAb、HBcAb,采用核酸扩增(PCR)荧光定量检测HBV-DNA含量。结果(1)研究组宫内感染率4.3%,明显低于对照组10.6%,两组比较差异有显著性意义(χ2=5.237,P<0.05);(2)研究组新生儿血清抗-HBs阳性率20.4%,明显高于对照组3.3%,差异有极显著意义(χ2=25.28,P<0.01);(3)研究组婴儿HBV感染率1.1%,明显低于对照组7.2%,两组比较差异有极显著性意义(χ2=7.3,P<0.01)。结论:产前用HBIG和新生儿HBIG联合乙肝疫苗免疫可降低慢性HBV感染率,阻断宫内感染的慢性化,提高产时感染的阻断效果。 展开更多
关键词 肝炎病毒 乙型 妊娠 免疫球蛋白 乙肝疫苗 母婴传播
下载PDF
肾移植患者接受HBcAb阳性供体时应用HBIg预防乙肝的安全性和有效性 被引量:1
14
作者 彭沙沙 林杰 +3 位作者 黄汉飞 刘涛 曾仲 段键 《山东医药》 CAS 2014年第21期1-3,共3页
目的:探讨肾移植(KT)患者接受HBcAb阳性供体时应用乙肝免疫球蛋白(HBIg)预防乙肝的安全性和有效性。方法选择行同种异体KT患者69例,受体术前均无乙肝,供体均为HBsAg阴性、HBcAb-IgM阳性。将其随机分为观察组39例,KT前后应用小剂... 目的:探讨肾移植(KT)患者接受HBcAb阳性供体时应用乙肝免疫球蛋白(HBIg)预防乙肝的安全性和有效性。方法选择行同种异体KT患者69例,受体术前均无乙肝,供体均为HBsAg阴性、HBcAb-IgM阳性。将其随机分为观察组39例,KT前后应用小剂量HBIg;对照组30例不用HBIg。比较两组术后不同时间的肝肾功能及术后12、36个月乙肝发生率。结果观察组术后发生急性排斥1例。随访3~36个月,观察组术后8、12个月死于肺部感染2例,对照组术后6、24个月死于肺部感染、暴发性肝炎各1例。观察组术后12、36个月乙肝发生率分别为0、2.6%,对照组分别为10.3%、17.9%,两组比较P均<0.05。两组术后12、24、36个月的血肌酐、总胆红素水平及24个月的肝功能异常率比较,P均<0.05。结论 KT患者接受HBcAb-IgM阳性者的供肾时,预防性应用HBIg进行被动免疫,可有效降低乙肝发生率,改善其术后肝肾功能,延长生存时间。 展开更多
关键词 肾移植 免疫球蛋白 乙型肝炎 预防
下载PDF
HBIG抑制HBsAg、HBV DNA分泌的体外实验研究 被引量:1
15
作者 彭忠田 谭德明 +3 位作者 黄顺玲 朱平安 刘菲 郭光辉 《中国感染控制杂志》 CAS 2008年第4期237-241,共5页
目的研究乙型肝炎免疫球蛋白(HBIG)对肝细胞的跨膜转运作用和对乙型肝炎病毒(HBV)感染细胞模型的乙型肝炎表面抗原(HBsAg)、HBVDNA分泌的抑制作用。方法用含HBIG的培养基培养QSG7701细胞,在不同时间点定量检测培养上清的抗HBs,... 目的研究乙型肝炎免疫球蛋白(HBIG)对肝细胞的跨膜转运作用和对乙型肝炎病毒(HBV)感染细胞模型的乙型肝炎表面抗原(HBsAg)、HBVDNA分泌的抑制作用。方法用含HBIG的培养基培养QSG7701细胞,在不同时间点定量检测培养上清的抗HBs,计算HBIG的透过率;用含HBIG的培养基培养HepG2.2.15细胞数天,或先以,定浓度的HBIG共培养,第3天后更换为不含HBIG的培养基继续培养细胞。于不同时间点定量检测培养上清的HBsAg、HBV DNA;用MTT比色试验观察药物的细胞毒性。结果浓度为0.1~0.4IU/mL的HBIG与QSG7701细胞共孵育48h时,细胞内约有38%~46%的HBIG。浓度为0.1~10.0IU/mL的HBIG作用第3、6.9天时能抑制HepG2,2.15细胞培养上清中HBsAg、HBV DNA的分泌(P〈0.01)。住尤药物继续培养的第5、7天,培养卜清中HBsAg浓度较有药物培养的第3天低且继续下降(P〈0.01),第9~11天逐步增高;培养上清HBV DNA水平在第5天时也较有药物培养的第3天低并继续下降(P〈0.01),第7~11大时逐步增高。结论在体外细胞实验中,HBIG能跨膜转运入肝细胞内,细胞内外的HBIG能抑制HBsAg、HBV DNA的分泌。 展开更多
关键词 肝炎 乙型 肝炎病毒 乙型 乙型肝炎免疫球蛋白 HEPG2.2.15细胞 HbV DNA
下载PDF
HBIG、无环鸟苷、干扰素联合对慢性乙型肝炎抗病毒效应观察 被引量:1
16
作者 黄华芳 熊开钧 +2 位作者 曾令兰 何生松 杨泽川 《中国病毒学》 CSCD 1994年第4期304-308,共5页
本文报道血清HBV复制标志阳性的慢乙肝54例,随机分为治疗组及对照组各27例进行HBIG、无环鸟苷、干扰素联合近、远期抗病毒效应观察。治疗组为无环鸟苷第一周按25~20mg/kg/d计后改17~15mg/kg/d×... 本文报道血清HBV复制标志阳性的慢乙肝54例,随机分为治疗组及对照组各27例进行HBIG、无环鸟苷、干扰素联合近、远期抗病毒效应观察。治疗组为无环鸟苷第一周按25~20mg/kg/d计后改17~15mg/kg/d×53天,共60天;人白细胞干扰素1×106U肌注每周3次×4周,后改1.0×106U肌注每周2次×6周,共10周;HBIG400U肌注隔日1次,共10周,对照组仅给予一般“保肝”药物。其中治疗组18例,对照组19例进行治后半年到2年追踪观察,结果近、远期HBcAg、DNAP、HBV-DNA阴转率治疗组均高于对照组,其中治疗组近、远期HBcAg,HBV-DNA阴转率均达40%以上,明显高于对照组(P<0.05~0.01),治疗组近、远期各有4例及2例HBsAg阴转,而对照组则无一例阴转,从近、远期综合抗病毒效应观察,治疗组全阴率分别为33.3%、44.4%,而对照组分别为3.79%及0%,P<0.01,治疗组无明显毒副反应。对比单用无环鸟苷,全阴率31.8%;无环鸟苷加干扰素两药联合全阴率37.5%,均有所提高,达到44.4%,值得进一步研究。 展开更多
关键词 hbig 无环鸟苷 干扰素 抗病毒药 乙型肝炎病毒
下载PDF
孕晚期用HBIG对HBV携带孕妇胎盘Toll样受体的影响 被引量:1
17
作者 张满云 吴彩林 肖小敏 《重庆医学》 CAS CSCD 北大核心 2013年第18期2057-2059,共3页
目的探讨孕晚期应用乙型肝炎免疫球蛋白(HBIG)干预对乙型肝炎病毒(HBV)携带孕妇胎盘组织TLR3、TLR4、TLR7表达的影响。方法收集2010年6~12月在该院产检并分娩的HBsAg(+)孕妇53例,正常孕妇10例。血清HBV-Ms和胎盘TLR3、TLR4、TLR7平均... 目的探讨孕晚期应用乙型肝炎免疫球蛋白(HBIG)干预对乙型肝炎病毒(HBV)携带孕妇胎盘组织TLR3、TLR4、TLR7表达的影响。方法收集2010年6~12月在该院产检并分娩的HBsAg(+)孕妇53例,正常孕妇10例。血清HBV-Ms和胎盘TLR3、TLR4、TLR7平均光密度分别采用ELISA和Envision免疫组织化学法检测。结果孕妇血清HBsAg(+)组,胎盘TLR3、TLR7的表达水平均较对照组高;胎盘HBsAg(-)组与胎盘HBsAg(+)组间,TLR3、TLR7表达水平比较差异无统计学意义;孕晚期使用HBIG者,胎盘中TLR3、TLR7的表达与未应用HBIG者比较差异无统计学意义。结论尚不能认为孕期应用HBIG可改变胎盘的TLR3、TLR7的表达。 展开更多
关键词 肝炎病毒 乙型 TOLL样受体 免疫球蛋白类
下载PDF
替诺福韦联合不同剂量HBIG在乙肝疫苗阻断HBV母婴传播中的效果 被引量:1
18
作者 张沝 张薇莉 赵隽 《中国生育健康杂志》 2022年第3期242-246,共5页
目的分析替诺福韦联合不同剂量乙肝免疫球蛋白(HBIG)在乙肝疫苗阻断乙肝病毒(HBV)母婴传播中的效果。方法选取2013年2月~2018年3月HBV感染的妊娠妇女[高载量(HBV DNA>1×10^(6)IU/mL)]1000例,分为乙肝免疫球蛋白100 IU组(替诺福... 目的分析替诺福韦联合不同剂量乙肝免疫球蛋白(HBIG)在乙肝疫苗阻断乙肝病毒(HBV)母婴传播中的效果。方法选取2013年2月~2018年3月HBV感染的妊娠妇女[高载量(HBV DNA>1×10^(6)IU/mL)]1000例,分为乙肝免疫球蛋白100 IU组(替诺福韦300 mg/d+新生儿出生后12 h内、1月肌注100 IU HBIG+0、1、6月注射10μg乙肝疫苗)和乙肝免疫球蛋白200 IU组(替诺福韦300 mg/d+新生儿出生后12 h内、1月肌注200 IU HBIG+0、1、6月注射10μg乙肝疫苗)。比较两组基线资料、新生儿情况、抗-HBs水平、母婴阻断效果、安全性、随访24个月情况。结果基线资料及新生儿情况在二组中的比较,均差异无统计学意义(P>0.05)。乙肝免疫球蛋白200 IU组出生1月、7月的抗-HBs水平[依次(295.8±42.9)mIU/mL、(764.1±146.3)mIU/mL]高于乙肝免疫球蛋白100 IU组[依次(250.9±33.7)mIU/mL、(737.2±152.1)mIU/mL],差异有统计学意义(P<0.05)。乙肝免疫球蛋白200 IU组阻断失败率(3.6%)低于乙肝免疫球蛋白100 IU组(6.6%),抗-HBs阳性率(96.4%)高于乙肝免疫球蛋白100 IU组(93.4%),差异有统计学意义(P<0.05)。24个月随访中,乙肝免疫球蛋白100 IU组失访9例(1.8%),乙肝免疫球蛋白200 IU组失访11例(2.2%);HBV DNA阳性、抗-HBs阳性在二组中的比较,差异无统计学意义(P>0.05)。二组替诺福韦不良反应比较差异无统计学意义(P>0.05);新生儿无不良反应。结论替诺福韦联合200 IU剂量HBIG在乙肝疫苗阻断HBV母婴传播中有助于短期内提高免疫保护及阻断效果,而长期效果与联合100 IU剂量HBIG相当,两种方案均安全可靠。 展开更多
关键词 乙型肝炎病毒 替诺福韦 hbig 乙肝疫苗 母婴传播
下载PDF
HBIG联合HBVac阻断HBV宫内感染的研究 被引量:1
19
作者 李银姬 岳亚飞 张树林 《中国优生与遗传杂志》 2005年第6期67-69,共3页
目的探讨孕期多次联合注射乙型肝炎免疫球蛋白(HBIG)和乙型肝炎疫苗(HBVac)阻断乙型肝炎病毒HBV)宫内感染效果。方法对30例HBsAg阳性孕妇从孕20周开始联合注射HBIG和HBVac,另23例未行注射的HBsAg阳性孕妇作对照。采用敏感特异的套式聚... 目的探讨孕期多次联合注射乙型肝炎免疫球蛋白(HBIG)和乙型肝炎疫苗(HBVac)阻断乙型肝炎病毒HBV)宫内感染效果。方法对30例HBsAg阳性孕妇从孕20周开始联合注射HBIG和HBVac,另23例未行注射的HBsAg阳性孕妇作对照。采用敏感特异的套式聚合酶链反应检测孕妇及新生儿血清及外周血单个核细胞(PBMC)中HBVDNA。结果阻断组和对照组新生儿血清HBVDNA检出率分别为10%(3/30)和34.8%(8/23),二组差异显著,而PBMC中HBVDNA检出率二组无显著性差异;阻断组孕妇血清HBVDNA水平下降率38.5%(10/26),而对照组10.5%(2/19),差异显著,PBMC中HBVDNA水平二组无显著性差异。结论孕期多次联合注射HBIG和HBVac可有效降低孕妇体内HBVDNA水平,从而降低HBV宫内感染率,但对孕妇PBMC中HBV影响不大,并不降低新生儿PBMC中HBVDNA的检出率。 展开更多
关键词 乙型肝炎病毒 宫内感染 乙型肝炎免疫球蛋白 乙型肝炎疫苗 聚合酶链反应 外周血单个核细胞
下载PDF
应用HBIG阻断乙肝病毒母婴传播的研究 被引量:2
20
作者 刘冬云 刘平英 张文馥 《天津医科大学学报》 2005年第2期274-275,共2页
目的:观察孕妇注射乙型肝炎免疫球蛋白(HBIG),新生儿生后接种乙型肝炎疫苗联合注射HBIG的干预方法,对乙型肝炎病毒(HBV)母婴垂直传播的阻断作用。方法:185例HBsAg(+)和/或HBeAg(+),无乙型肝炎症状的孕妇分为干预组(108例孕妇,109例新生... 目的:观察孕妇注射乙型肝炎免疫球蛋白(HBIG),新生儿生后接种乙型肝炎疫苗联合注射HBIG的干预方法,对乙型肝炎病毒(HBV)母婴垂直传播的阻断作用。方法:185例HBsAg(+)和/或HBeAg(+),无乙型肝炎症状的孕妇分为干预组(108例孕妇,109例新生儿)和对照组(77例孕妇,77例新生儿)。干预组自怀孕28周起每月肌注HBIG200IU,两组新生儿出生时、1月和6月接种乙型肝炎疫苗和多次注射HBIG。所有婴儿取血检测HBsAg和HBeAg等乙型肝炎血清标记物,并随访至生后1年。结果:在出生时、6月和12月,干预组婴儿HBsAg(+)和/或HBeAg(+)例数皆低于对照组。结论:应用该方法对阻断HBV母婴垂直传播有效。 展开更多
关键词 乙型肝炎病毒 垂直传播 乙型肝炎免疫球蛋白
下载PDF
上一页 1 2 26 下一页 到第
使用帮助 返回顶部